Global /Australia /Healthcare /Medical Devices /IRX

Nexalis Therapeutics Ltd.

IRX

• ASX: IRX • Delayed

0.0280AUD 0%

0.0197 USD

As of 7 June 2026, Nexalis Therapeutics Ltd. has a market cap of $4.92M USD, ranking #44556 globally and #1574 in Australia. It ranks #3946 in the Healthcare sector, and #833 in the Medical Devices industry.

Global Rank

44556

Country Rank

1574

Sector Rank

3946

Industry Rank

833

Key Stats

Market Cap

$4.92MUSD

6.9M AUD

Enterprise Value

$4.75MUSD

6.75M AUD

Revenue (TTM)

$595.1KUSD

833.9K AUD

Net Income (TTM)

-$946.37KUSD

-1.33M AUD

Profit Margin

-159%

PS Ratio

8.3

PB Ratio

-7.9

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Medical Devices

CEO

Darryl Davies open_in_new

Founded

2016

Website

inhalerx.com.au open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	27%	27%	7.7%	-24%	17%	27%	-53%	-77%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	IRX InhaleRx Ltd ISIN: AU0000179475 Shares Out.: Shares Outstanding: 246.257M¹ Shares Float: 165.47M² TV: TradingView: ASX: IRX SA: Stock Analysis: ASX: IRX YF: Yahoo Finance: IRX.AX GF: Google Finance: ASX: IRX BA: Barron's: IRX MS: Morningstar: XASX: IRX	0.0280 AUD	TV: TradingView: ASX: IRX SA: Stock Analysis: ASX: IRX YF: Yahoo Finance: IRX.AX GF: Google Finance: ASX: IRX BA: Barron's: IRX MS: Morningstar: XASX: IRX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Nexalis Therapeutics Ltd.

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.

Similar Companies

Industry: Medical Devices (Australia)

Name	Market Cap (USD) diff.	PE	Country
Cochlear Ltd. ASX: COH	$4.2B 5.89B AUD 85K%	17.1	Australia
EBOS Group Ltd. NZE: EBO	$2.55B 4.34B NZD 52K%	16.0	Australia
Clarity Pharmaceuticals Ltd. ASX: CU6	$786.34M 1.1B AUD 16K%	-	Australia
Nanosonics Ltd. ASX: NAN	$743.12M 1.04B AUD 15K%	52.3	Australia
Tetratherix Ltd. ASX: TTX	$171.0M 239.61M AUD 3K%	-	Australia
Orthocell Ltd. ASX: OCC	$170.38M 238.75M AUD 3K%	-	Australia

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 4M%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 3M%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 3M%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 3M%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 2M%	38.3	United States
Medtronic plc NYSE: MDT	$101.9B 2M%	22.2	Ireland

chevron_leftBack